Mario E. Lacouture

28.3k total citations · 4 hit papers
375 papers, 15.1k citations indexed

About

Mario E. Lacouture is a scholar working on Oncology, Dermatology and Molecular Biology. According to data from OpenAlex, Mario E. Lacouture has authored 375 papers receiving a total of 15.1k indexed citations (citations by other indexed papers that have themselves been cited), including 228 papers in Oncology, 145 papers in Dermatology and 81 papers in Molecular Biology. Recurrent topics in Mario E. Lacouture's work include Colorectal Cancer Treatments and Studies (130 papers), Chemotherapy-related skin toxicity (99 papers) and Cancer Treatment and Pharmacology (50 papers). Mario E. Lacouture is often cited by papers focused on Colorectal Cancer Treatments and Studies (130 papers), Chemotherapy-related skin toxicity (99 papers) and Cancer Treatment and Pharmacology (50 papers). Mario E. Lacouture collaborates with scholars based in United States, France and Germany. Mario E. Lacouture's co-authors include Shenhong Wu, Jedd D. Wolchok, Michael A. Postow, V. Sibaud, Katja Schindler, David B. Page, Jarushka Naidoo, Bob T. Li, Louise C. Connell and Viswanath Reddy Belum and has published in prestigious journals such as Nature, JAMA and Journal of Clinical Oncology.

In The Last Decade

Mario E. Lacouture

355 papers receiving 14.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies

2015 1.2k citations Mario E. Lacouture, Jedd D. Wolchok et al. profile →
Mechanisms of cutaneous toxicities to EGFR inhibitors

2006 547 citations Mario E. Lacouture profile →
Immune checkpoint inhibitor–related dermatologic adverse events

2020 298 citations Donald Y.M. Leung, Andrea P. Moy et al. profile →
Management of Dermatologic Events Associated With the Nectin-4-directed Antibody-Drug Conjugate Enfortumab Vedotin

2022 87 citations Mario E. Lacouture, Anisha B. Patel et al. The Oncologist profile →

Peers

Countries citing papers authored by Mario E. Lacouture

Since Specialization

Citations

This map shows the geographic impact of Mario E. Lacouture's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mario E. Lacouture with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mario E. Lacouture more than expected).

Fields of papers citing papers by Mario E. Lacouture

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mario E. Lacouture. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mario E. Lacouture. The network helps show where Mario E. Lacouture may publish in the future.

Co-authorship network of co-authors of Mario E. Lacouture

This figure shows the co-authorship network connecting the top 25 collaborators of Mario E. Lacouture. A scholar is included among the top collaborators of Mario E. Lacouture based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mario E. Lacouture. Mario E. Lacouture is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Racial and Ethnic Disparities in Persistent Chemotherapy-Induced Alopecia Among Women With Breast Cancer 2026 ·JAMA Network Open ·(unknown), Lukas Kraehenbuehl, (unknown), (unknown), Jiyeon Kim, (unknown), (unknown), Shari Goldfarb, (unknown), (unknown), (unknown), (unknown), (unknown), Mario E. Lacouture, (unknown)	0
2	Immunologic Profiling of Immune-Related Cutaneous Adverse Events with Checkpoint Inhibitors Reveals Polarized Actionable Pathways 2024 ·Clinical Cancer Research ·Mario E. Lacouture, Elena Goleva, Neil J. Shah, Veronica Rotemberg, Lukas Kraehenbuehl, (unknown), Taha Merghoub, (unknown), (unknown), (unknown), (unknown), Andrea P. Moy, Taras Lyubchenko, (unknown), Clifton F. Hall, Evgeny Berdyshev, James Crooks, Ryan Weight, Jeffrey A. Kern, Donald Y.M. Leung	13
3	Management of immune-related cutaneous adverse events with dupilumab 2023 ·Journal for ImmunoTherapy of Cancer ·(unknown), (unknown), (unknown), Andrea P. Moy, Stephen W. Dusza, (unknown), (unknown), Yelena Y. Janjigian, Lukas Kraehenbuehl, Elizabeth Quigley, Paul B. Chapman, Mario E. Lacouture, Alina Markova	25
4	Expert guidance on prophylaxis and treatment of dermatologic adverse events with Tumor Treating Fields (TTFields) therapy in the thoracic region 2023 ·Frontiers in Oncology ·Milan J. Anadkat, Mario E. Lacouture, Adam Friedman, Zachary D. Horne, Jae U. Jung, Benjamin H. Kaffenberger, Sujith Kalmadi, Liza G. Ovington, Rupesh Kotecha, (unknown), Federica Grosso	9
5	Management of Dermatologic Events Associated With the Nectin-4-directed Antibody-Drug Conjugate Enfortumab Vedotin breakdown → 2022 ·The Oncologist ·Mario E. Lacouture, Anisha B. Patel, Jonathan E. Rosenberg, Peter H. O’Donnell	87
6	Reducing Skin Toxicities from EGFR Inhibitors with Topical BRAF Inhibitor Therapy 2021 ·Cancer Discovery ·Mario E. Lacouture, Zev A. Wainberg, Anisha B. Patel, Milan J. Anadkat, Salomon M. Stemmer, Einat Shacham‐Shmueli, Egmidio Medina, (unknown), (unknown), Antoni Ribas	16
7	US Cutaneous Oncodermatology Management (USCOM): A Practical Algorithm 2021 ·Journal of Drugs in Dermatology ·Mario E. Lacouture, Jennifer Choi, Alice Y. Ho, Jonathan S. Leventhal, Beth N. McLellan, Anneke Andriessen, Maxwell Sauder, (unknown)	5
8	Beyond Steroids: Immunosuppressants in Steroid-Refractory or Resistant Immune-Related Adverse Events 2021 ·Journal of Thoracic Oncology ·Jia Luo, Jason Beattie, (unknown), Hira Rizvi, Jacklynn V. Egger, Jeffrey A. Kern, Donald Y.M. Leung, Mario E. Lacouture, Mark G. Kris, (unknown), Bianca Santomasso, David M. Faleck, Matthew D. Hellmann	74
9	Neurokinin-1 antagonist orvepitant for EGFRI-induced pruritus in patients with cancer: a randomised, placebo-controlled phase II trial 2020 ·BMJ Open ·Bruno Vincenzi, (unknown), Ajay Duggal, Pamela Guglielmini, Peter Q. Harris, David M. Jackson, Mario E. Lacouture, Emiliangelo Ratti, Giuseppe Tonini, (unknown), Sonja Ständer	11
10	Randomized controlled trial of cryotherapy to prevent paclitaxel-induced peripheral neuropathy (RU221511I); an ACCRU trial 2019 ·The Breast ·Kathryn J. Ruddy, Jennifer Le‐Rademacher, Mario E. Lacouture, Mary Wilkinson, Adedayo A. Onitilo, (unknown), (unknown), Travis Dockter, Angelina D. Tan, Andreas S. Beutler, Charles L. Loprinzi	38
11	Safety and Efficacy of Re-treating with Immunotherapy after Immune-Related Adverse Events in Patients with NSCLC 2018 ·Cancer Immunology Research ·Fernando C. Santini, Hira Rizvi, Andrew J. Plodkowski, Ai Ni, Mario E. Lacouture, Maya Gambarin‐Gelwan, Olivia Wilkins, Elizabeth Panora, Darragh Halpenny, Niamh M. Long, Mark G. Kris, Charles M. Rudin, Jamie E. Chaft, Matthew D. Hellmann	263
12	Novel activating BRAF fusion identifies a recurrent alternative mechanism for ERK activation in pediatric Langerhans cell histiocytosis 2017 ·Pediatric Blood & Cancer ·Sara Zarnegar, Benjamin H. Durham, Pallavi Khattar, Neerav Shukla, Ryma Benayed, Mario E. Lacouture, Ehud Lavi, David Lyden, Eli L. Diamond, Ira J. Dunkel, Omar Abdel‐Wahab	17
13	Pilot Trial of Combined BRAF and EGFR Inhibition in BRAF -Mutant Metastatic Colorectal Cancer Patients 2015 ·Clinical Cancer Research ·Rona Yaeger, Andrea Cercek, Eileen M. O’Reilly, Diane Reidy‐Lagunes, Nancy E. Kemeny, (unknown), Marinela Capanu, Marc J. Gollub, Neal Rosen, Michael F. Berger, Mario E. Lacouture, Efsevia Vakiani, Leonard B. Saltz	221
14	Prospective Blinded Study of BRAF V600E Mutation Detection in Cell-Free DNA of Patients with Systemic Histiocytic Disorders 2014 ·Cancer Discovery ·David M. Hyman, Eli L. Diamond, Cecile Rose T. Vibat, (unknown), Jason C. Poole, Minal Patel, Veronica R. Holley, Goran Cabrilo, Timothy T. Lu, Maria E. Arcila, Young Rock Chung, Raajit K. Rampal, Mario E. Lacouture, Neal Rosen, Funda Meric‐Bernstam, José Baselga, Razelle Kurzrock, Mark G. Erlander, Filip Jankú, Omar Abdel‐Wahab	84
15	Incidence and risk of rash to mTOR inhibitors in cancer patients – a meta-analysis of randomized controlled trials 2014 ·Acta Oncologica ·(unknown), Mario E. Lacouture, Shenhong Wu	6
16	Phase II Trial of MEK Inhibitor Selumetinib (AZD6244, ARRY-142886) in Patients with BRAFV600E/K-Mutated Melanoma 2013 ·Clinical Cancer Research ·Federica Catalanotti, David B. Solit, Melissa Pulitzer, Michael F. Berger, Sasinya N. Scott, Tunç Iyriboz, Mario E. Lacouture, Katherine S. Panageas, Jedd D. Wolchok, Richard D. Carvajal, Gary K. Schwartz, Neal Rosen, Paul B. Chapman	112
17	Atypical Melanocytic Proliferations and New Primary Melanomas in Patients With Advanced Melanoma Undergoing Selective BRAF Inhibition 2012 ·Journal of Clinical Oncology ·Lisa Zimmer, Uwe Hillen, Elisabeth Livingstone, Mario E. Lacouture, Klaus J. Busam, Richard D. Carvajal, Friederike Egberts, Axel Hauschild, Mohammed Kashani–Sabet, Simone M. Goldinger, Reinhard Dummer, Georgina V. Long, Grant A. McArthur, André Scherag, Antje Sucker, Dirk Schadendorf	167
18	Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of TH-302, a Hypoxia-Activated Prodrug, in Patients with Advanced Solid Malignancies 2011 ·Clinical Cancer Research ·Glen J. Weiss, Jeffrey R. Infante, E. Gabriela Chiorean, Mitesh J. Borad, Johanna C. Bendell, Julian R. Molina, Raoul Tibes, Ramesh K. Ramanathan, (unknown), Suzanne F. Jones, Mario E. Lacouture, Virginia K. Langmuir, (unknown), Stew Kroll, Howard A. Burris	122
19	Histopathologic and Immunohistochemical Characterization of Rash to Human Epidermal Growth Factor Receptor 1 (HER1) and HER1/2 Inhibitors in Cancer Patients 2010 ·Clinical Cancer Research ·Beatrice Nardone, Kimberly Nicholson, Marissa Newman, Joan Guitart, Pedram Gerami, Nicholas Talarico, Ximing J. Yang, Alfred Rademaker, Dennis P. West, Mario E. Lacouture	34
20	Clinical management of EGFRI dermatologic toxicities: US perspective. 2007 ·PubMed ·Mario E. Lacouture, Jonathan Cotliar, Edith Mitchell	18

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact